David vs. Goliath
One sales rep took on a $27 billion corporation. She won.
Angie Kelly is the founder of Disclosure Strategy and a former federal whistleblower whose case helped secure a $762 million settlement against Amgen, one of the world's largest biotechnology companies.
$762M
Total settlement
5 years
Legal battle
Guilty
Criminal plea
The story
From 2002 to 2005, Angie Kelly worked as an oncology pharmaceutical sales representative at Amgen Corporation. During her time there, she witnessed something that troubled her deeply: a coordinated scheme to pay illegal kickbacks to doctors and hospitals, pushing them to prescribe Amgen's powerful anemia drug Aranesp for uses the FDA had never approved.
These weren't minor violations. The off-label marketing put patients at risk. Medicare and Medicaid were being defrauded. And the company showed no signs of stopping.
Angie made a decision that would change her life: she filed a lawsuit under the False Claims Act.
In 2007, she filed her case in federal court. She wasn't alone in seeing the fraud. Nine other whistleblowers independently filed their own cases against Amgen, each having witnessed the same pattern of misconduct. The Department of Justice ultimately combined these cases into one consolidated action.
What followed was a five-year legal battle against one of the most powerful companies in biotechnology, with a market cap exceeding $27 billion.
The victory
On December 19, 2012, the Department of Justice announced a global settlement with Amgen totaling $762 million:
- $612 million civil settlement
- $136 million criminal fine
- $14 million criminal forfeiture
More importantly, Amgen pleaded guilty to federal criminal charges for introducing a misbranded drug into interstate commerce. The company was forced to sign a Corporate Integrity Agreement with the Office of Inspector General.
The case was covered by The New York Times, Reuters, and major industry publications. It became one of the landmark pharmaceutical fraud cases of its era.
What she exposed
Illegal kickbacks
Payments to doctors and hospitals to prescribe Amgen medications, violating the Anti-Kickback Statute
Off-label marketing
Promotion of drugs for uses not approved by the FDA, often putting patients' health at risk
Medicare and Medicaid fraud
Federal healthcare programs paying for unnecessary or inappropriate treatments
Why she built Disclosure Strategy
After her case concluded, Angie didn't walk away. She had seen firsthand how the process works, what mistakes people make, and how easily whistleblowers can lose before they ever have a chance to win.
She became an investigator and Chief Fraud Analyst, dedicating herself to helping others navigate the same journey she took. Through years of advising potential whistleblowers, she saw the same patterns repeat:
- People disclosed too early, before building their case
- People trusted the wrong parties, including HR departments and internal counsel
- People underestimated retaliation until it was too late
- People lost leverage they could never recover
Disclosure Strategy exists to stop those mistakes before they happen.
Her approach
Outcome-focused
Every decision is evaluated against one question: does this improve the chance of a successful outcome?
Protecting your position
Protecting your options and bargaining power throughout the process
Anticipating retaliation
Predicting and preparing for retaliation before it escalates
What to do first
Choosing the right order of disclosure to maximize protection and impact